Duran, Ignacio
Carles, Joan
Bulat, Iurie
Hellemans, Peter
Mitselos, Anna
Ward, Peter
Jiao, James
Armas, Danielle
Chien, Caly
Funding for this research was provided by:
Janssen Research and Development
Article History
First Online: 27 April 2020
Compliance with Ethical Standards
:
: Ignacio Duran reports personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pharmacyclics, Roche Genentech, and Sanofi, non-financial support from AstraZeneca, Ipsen, and Roche Genentech, and grants from AstraZeneca and Roche Genentech outside the submitted work. Joan Carles reports advisory roles for Astellas, Bayer, Bristol-Myers Squibb, Johnson & Johnson, MSD Oncology, Pfizer, Roche, and Sanofi, and speakers’ bureau roles for Asofarma, Astellas, Bayer, and Johnson & Johnson outside the submitted work. Iurie Bulat has no conflicts of interest that are directly relevant to the content of this article. Danielle Armas reports support from Janssen to her employer, Celerion, during the conduct of the study. Peter Hellemans, Anna Mitselos, Peter Ward, James Jiao, and Caly Chien are current or former employees of Janssen Research & Development and hold/held stock in Johnson & Johnson.
: Protocols of both studies were reviewed by an independent ethics committee and institutional review board, and both studies were conducted in accordance with Good Clinical Practice and applicable regulatory requirements.
: Participants in both studies provided written informed consent.